WHOOP Announces Global Partnership with Cristiano Ronaldo
13.5.2024 13:00:00 EEST | Business Wire | Press release
WHOOP, the human performance company, today announced Cristiano Ronaldo, the legendary football icon, as an official global ambassador and investor. This represents one of Ronaldo's most significant investments to date. Ronaldo joins the company’s growing roster of global ambassador investors, including Patrick Mahomes, Michael Phelps, Eli Manning, Rory McIlroy, and more. Announced earlier this morning on Instagram Live, this partnership signifies the company’s global growth trajectory and commitment to revolutionizing the world of human performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513817139/en/
WHOOP announces global partnership with Cristiano Ronaldo. (Photo: Business Wire)
The partnership between WHOOP and Ronaldo is an obvious one. Ronaldo’s success has been built on an obsession to perform at the highest levels. First to training, last to leave - former teammates speak of his dedication to self improvement having been the driving force behind his success. Cristiano is still performing at a very high level. He was the highest scorer in the World in 2023, is currently the top scorer in the Saudi Pro League, and is preparing for the Euros this summer. Ronaldo and WHOOP will partner on product development and leverage data-driven insights to help deliver the best health and fitness coaching for athletes and humanity broadly.
“Cristiano has been a WHOOP member for a number of years, and we’re proud to strengthen our relationship further through this partnership,” said Will Ahmed, WHOOP Founder and CEO. “Cristiano’s relentless pursuit of improvement and perfection mirrors our mission. We are looking forward to collaborating with him to share unprecedented insights into his training and recovery methods. Together, we'll unveil exciting product collaborations to enhance the WHOOP experience for our members.”
Cristiano Ronaldo, one of the greatest players in the history of football, has achieved unparalleled success across various prestigious football leagues worldwide, including the Premier League (Manchester United 2003-09; 2021-23), LaLiga (Real Madrid 2009-18), Serie A (Juventus 2018-22), and most recently, the Saudi Pro League (Al Nassr 2022-Present). As the leading scorer in the history of top-level association football globally, with 891 goals and counting, Ronaldo has won seven league titles and five UEFA Champions Leagues and is a five-time winner of the Ballon d'Or.
Ronaldo has also represented his home country of Portugal in international competition with the senior team since 2003, appearing in 206 matches to date and scoring 128 goals. His contributions have led Portugal to victory in the UEFA European Championship in 2016 and the UEFA Nations League title in 2019.
“WHOOP has had a transformative impact on my life both on and off the pitch, and I’m honored to join the team as an investor,” said Cristiano Ronaldo. “I wear WHOOP while training, sleeping, and recovering. It’s been one of the most important tools helping me elevate my game and monitor my health. I look forward to working with WHOOP to continue to raise the bar on WHOOP features and coaching.”
The partnership and investment from Ronaldo coincide with the announcement of WHOOP expanding its availability to Gulf Cooperation Council regions - Saudi Arabia, Qatar, Kuwait, Bahrain - in addition to Hong Kong, Israel, Korea, and Taiwan. Furthermore, by the time of the announcement, WHOOP will have extended its shipping services to India, Mexico, and Brazil, ensuring a seamless experience for members across these markets.
For more information on WHOOP x Ronaldo, please visit www.whoop.com/cr7.
ABOUT WHOOP
WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP serves professional athletes, Fortune 500 CEOs, executives, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance. WHOOP Unite is a comprehensive solution dedicated to supporting organizations across a wide range of industries with coaching, organizational insights, and health programs. Studies show WHOOP can positively change behavior, increase sleep, and improve physiological biomarkers. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. The latest round of financing made WHOOP the world's most valuable standalone wearables company. Visit WHOOP.com for more information and connect with WHOOP on Instagram, Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513817139/en/
Contact information
PRESS CONTACT:
Will McClaran
Jack Taylor PR
whoop@jacktaylorpr.com
GCC PRESS CONTACT:
Aaron Illathu
Jack Taylor PR
aaron@jacktaylorpr.com
+971 585 575 2884
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom